DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Bliss GVS Pharma Limited (BLISSGVS) share price today?

Bliss GVS Pharma Limited (BLISSGVS) is trading at ₹654.85 on the NSE, up 0.08% on the day. Source: DocStoX.

What is the PE ratio of Bliss GVS Pharma Limited?

Bliss GVS Pharma Limited has a price-to-earnings (PE) ratio of 53.5 in the Healthcare sector.

What is the market capitalisation of Bliss GVS Pharma Limited?

Bliss GVS Pharma Limited has a market capitalisation of approximately ₹7,005 crore.

Is Bliss GVS Pharma Limited a profitable company?

Bliss GVS Pharma Limited generates a return on equity of 10.8% with a net profit margin of 14.5%. That is a modest return on shareholder capital.

What is the 52-week high and low of BLISSGVS?

Bliss GVS Pharma Limited (BLISSGVS) has traded between ₹118 and ₹739.9 over the past 52 weeks, against a current price of ₹654.85.

Does Bliss GVS Pharma Limited pay a dividend?

Yes. Bliss GVS Pharma Limited currently offers a dividend yield of 0.21%. Dividend payments depend on the board's declaration each year.

Bliss GVS Pharma Limited

₹654.85▲ +0.55 (+0.08%)

BLISSGVS·NSE·Healthcare

Market Cap

7005.05 Cr

PE Ratio

53.54

Volume

1,29,277

Day High - Low

658.00 - 640.00

52W High-Low

739.90 - 118.00

₹654.85▲ +0.55 (+0.08%)

Market Cap7005.05 Cr

PE Ratio53.54

Volume1,29,277

Day High - Low658.00 - 640.00

52W High-Low739.90 - 118.00

Bliss GVS Pharma Limited (BLISSGVS): company summary

The company's business is improving, with annual revenue rising 14.5% and annual net profit surging 49.7%.

Bliss GVS Pharma Limited (BLISSGVS) is a small-cap Healthcare company valued at ₹7,005 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Bliss GVS Pharma Limited last traded at ₹654.85, modestly up 0.08% on the day.
Recent developments: On 2026-09-29, Anupam Rasayan completed the acquisition of a 48.2% stake in Bliss GVS Pharma for ₹1,750 crore, marking its third inorganic transaction. The deal was structured through a promoter/Share Purchase Agreement (SPA) route at ₹299 per share, with an open offer and a small on-market top-up. On 2026-07-22, Anupam Rasayan launched an ₹829 crore open offer for Bliss GVS Pharma at ₹299 per share as part of its ₹1,370 crore acquisition plan.
Financial performance: The company's business is improving, with annual revenue rising 14.5% and annual net profit surging 49.7%. The latest quarter saw revenue jump 38.0% and net profit climb 16.7% compared to the same quarter a year earlier. Net profit margin expanded 3.4 percentage points to 14.5%, while return on capital employed remained strong at 16.6%.
Valuation multiples: The stock trades at 53.5 times earnings, a premium to the Healthcare median of 32.0, 6.27 times book value. It yields 0.2%.
Things to watch: The stock is 7.6% below its 52-week high, and promoter holding fell 0.35 percentage points in the quarter. Foreign institutional holding dropped 2.38 percentage points, while domestic institutional holding rose 4.43 percentage points. The company's market cap is ₹7,239 crore, placing it in the small-cap category.
Where it stands: Bliss GVS Pharma reported strong growth in both revenue and net profit, with the latest quarter showing significant year-over-year improvements. The company's net profit margin expanded, and its return on capital employed remained robust. However, the stock is trading below its 52-week high, and promoter holdings have slightly declined.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

5.5/10

Fair

Fair Value

ROE

10.82%

Average

P/E

53.54x

Expensive

Debt / Equity

0.02

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹640.00

₹658.00

52W₹118.00

₹739.90

DocStoX take

Supported by risk (8.3) and momentum (7.5), but held back by valuation (0.0). Risk looks strong at 8.3, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

5.5

/10

Fair

Quality

Solid

ROE 10.8%

Valuation

Expensive

P/E 53.5×

Growth

Steady

Revenue +9.9% 5Y CAGR

Risk

Low risk

D/E 0.02

Momentum

Strong

86% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹655

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹7,005 Cr

52W High / Low

₹740 / ₹118

Dividend Yield

0.21%

Promoter Holding

35.01%

EPS (TTM)

₹12.23

Book Value

₹112.76

Key highlights

Low leverage — D/E 0.02
Profitable in all of the last 5 years
Valuation is weak (0.0/10)

2 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Bliss GVS Pharma Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Bliss GVS Pharma Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Bliss GVS Pharma Limited with peers

Bliss GVS Pharma Limited vs Sun Pharmaceutical Industries Limited Bliss GVS Pharma Limited vs Divi's Laboratories Limited Bliss GVS Pharma Limited vs Torrent Pharmaceuticals Limited Bliss GVS Pharma Limited vs Apollo Hospitals Enterprise Limited Bliss GVS Pharma Limited vs Zydus Lifesciences Limited Bliss GVS Pharma Limited vs Laurus Labs Limited

Related tools & concepts

Value Bliss GVS Pharma Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

BLISSGVS newsLatest coverage & filings Open screenerFilter the whole market